Investigation of the maximum optimal dosage and efficacy of lenalidomide for the treatment of relapsed and refractory multiple myeloma. - Investigation of the maximum optimal dosage and efficacy of lenalidomide for the treatment of relapsed and refractory multiple myeloma.

Kurume University Hospital Division of Hematology and Oncology0 个研究点目标入组 38 人开始时间: 2013年3月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) previously administered lenalidomide 2) hypersensitive reaction for lenalidomide, thalidomide and dexamethazone 3) non-secretory myeloma, solitary plasmacytoma, plasmacell leukemia and POEMS syndrome 4) CTCAE more than grade 3 neutropenia, thrombocytopenia 5) HBsAg is positive 6) HCV is positive, HIV is positive 7) uncontrollable liver dysfunction, renal insufficiency, cardiac dysfunction, respiratory dysfunction, diabetus mellitus, hypertension and infection 8) double cancer 9) psychoneurotic disorder, depression state or history 10) a case for difficult to collect QoL score 11) pregnant female, possible pregnancy or durling lactation 12) pulomonary fibrosis and interstitial pneumonitis interstitial shadow on chest CT, even if no sympton 13) physicians' decision

发起方

Kurume University Hospital Division of Hematology and Oncology